Meet Stephanie Finnegan and Nicole Brenna at SCOPE 2024 | Cromos Pharma

Meet Cromos Pharma at the SCOPE SUMMIT 2024

We are pleased to inform you that Stephanie Finnegan, Chief Operating Officer at Cromos Pharma, and Nicole Brenna, our Director of US Business Development, will be participating in the SCOPE SUMMIT 2024, scheduled from February 11 to 14, 2024, in Orlando, FL.

Stephanie and Nicole are enthusiastic about engaging with potential partners and clients to understand their clinical development initiatives better. To schedule a meeting and explore discussions regarding your upcoming clinical trials, feel free to contact us directly at inquiry@cromospharma.com

CONTACT

INQUIRY@CROMOSPHARMA.COM

To arrange an introductory meeting and find out how our experience can benefit your next clinical project.

OUR PUBLICATIONS

Rezdiffra Approval | Cromos Pharma
Rezdiffra Approval Sheds Light on the Challenges of NASH Diagnosis and Fibrosis Identification
Clinical Trials in Georgia 2024 | Cromos Pharma
Сlinical Trials in Georgia 2024
Clinical Research Focus 27bth Edition April | Cromos Pharma
Clinical Research Focus. 27th Edition
The Impact of US-China Tensions on Biopharmaceutical Innovation | Cromos Pharma
Navigating the Challenges: The Impact of US-China Tensions on Biopharmaceutical Innovation
Hungary Country Profile 2024 | Cromos Pharma
Exploring Clinical Trial Opportunities: Hungary’s 2024 Country Profile
World Kidney Day 2024 | Cromos Pharma
World Kidney Day 2024
Clinical Research Focus 26th edition | Cromos Pharma
Clinical Research Focus. 26th Edition
Celebrating Rare Disease Day 2024 | Cromos Pharma
Celebrating Rare Disease Day 2024
Clinical Research Focus 25th edition | Cromos Pharma
Clinical Research Focus. 25th Edition
The FDA’s Latest Guidance on Human Genome Editing | Cromos Pharma
Navigating the Future of Gene Therapy
Regulatory Updates and Simplified Processes in Türkiye | Cromos Pharma
Türkiye’s Emerging Role in Clinical Research: Regulatory Updates and Simplified Processes
J.P. Morgan Healthcare Conference 2024 Key Insights | Cromos Pharma
J.P. Morgan’s Healthcare Conference: A Glimpse into the Optimistic Pulse of 2024
Pragmatic Clinical Trials in 2024 | Cromos Pharma
Pragmatic Clinical Trials in 2024
Clinical Research Focus 24th edition | Cromos Pharma
Clinical Research Focus. 24th Edition
Key Insights from ASH 2023 | Cromos Pharma
Exploring Groundbreaking Advances: Key Insights from ASH 2023
Key Highlights in Clinical Research and Healthcare for 2023 | Cromos Pharma
Key Highlights in Clinical Research and Healthcare for 2023
Clinical Intelligence Report 7th edition December
Revitalizing Biotech: Navigating Efficient Clinical Trials Amid Financial Constraints
FDA approved Gene Therapies for Sickle Cell Disease | Cromos Pharma
FDA Greenlights Groundbreaking Gene Therapies for Sickle Cell Disease
Clinical Research Focus #23 December | Cromos Pharma
Clinical Research Focus. 23rd Edition
Clinical Intelligence Report 6th edition November
Shining a Spotlight on Diabetes Awareness Month: The Vital Role of Clinical Trials
Navigating the Challenging Biotech Funding Landscape | Cromos Pharma
Navigating the Challenging Biotech Funding Landscape
Clinical Research Focus | 22nd Edition. November | Cromos Pharma
Clinical Research Focus. 22nd Edition
Cromos Pharma's CEO Reflections on ESMO 2023
Cromos Pharma’s CEO Reflections on ESMO 2023: A Glimpse into The Future Of Oncology
Fit-for-Purpose Biotech – CRO Collaboration – The FSP Model | Cromos Pharma
Fit-for-Purpose Biotech – CRO Collaboration: The FSP Model
Project Optimus - Enhancing Oncology Drug Dosage Optimization | Cromos Pharma
Enhancing Oncology Drug Dosage Optimization: Project Optimus
Clinical Research Focus | 21st Edition. October | Cromos Pharma
Clinical Research Focus. 21st Edition
Debating the Role of Interchangeability in Biosimilar Development
Debating the Role of Interchangeability in Biosimilar Development
Clinical Research Focus 20th Edition September | Cromos Pharma
Clinical Research Focus. 20th Edition
EMA Releases a Reflection Paper on the Role of AI in Drug Development
EMA Releases a Reflection Paper on the Role of AI in Drug Development
Regulatory Landscapes of GMO Research Programs | Cromos Pharma
Cromos Pharma Contemplates Complex International GMO Research Program Regulations